Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated:  12/31/1969
Great Lakes Medical Research
2051
mi
from 91732
Mentor, OH
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated: 12/31/1969
Great Lakes Medical Research
2051
mi
from 91732
Mentor, OH
Click here to add this to my saved trials
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated:  12/31/1969
ClinSearch, LLC
1862
mi
from 91732
Chattanooga, TN
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated: 12/31/1969
ClinSearch, LLC
1862
mi
from 91732
Chattanooga, TN
Click here to add this to my saved trials
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated:  12/31/1969
New Phase Research & Development
1923
mi
from 91732
Knoxville, TN
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated: 12/31/1969
New Phase Research & Development
1923
mi
from 91732
Knoxville, TN
Click here to add this to my saved trials
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated:  12/31/1969
Aztec Medical Research, Inc.
1372
mi
from 91732
Channelview, TX
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated: 12/31/1969
Aztec Medical Research, Inc.
1372
mi
from 91732
Channelview, TX
Click here to add this to my saved trials
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated:  12/31/1969
Gastroenterology Research Of San Antonio
1188
mi
from 91732
San Antonio, TX
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated: 12/31/1969
Gastroenterology Research Of San Antonio
1188
mi
from 91732
San Antonio, TX
Click here to add this to my saved trials
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated:  12/31/1969
Advanced Rx Clinical Research Group, Inc
21
mi
from 91732
Westminster, CA
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated: 12/31/1969
Advanced Rx Clinical Research Group, Inc
21
mi
from 91732
Westminster, CA
Click here to add this to my saved trials
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated:  12/31/1969
Endoscoopy Center of AR
1459
mi
from 91732
Little Rock, AR
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated: 12/31/1969
Endoscoopy Center of AR
1459
mi
from 91732
Little Rock, AR
Click here to add this to my saved trials
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Associates
1785
mi
from 91732
Huntsville, AL
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Associates
1785
mi
from 91732
Huntsville, AL
Click here to add this to my saved trials
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated:  12/31/1969
E Squared Research, Inc.
1784
mi
from 91732
Huntsville, AL
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated: 12/31/1969
E Squared Research, Inc.
1784
mi
from 91732
Huntsville, AL
Click here to add this to my saved trials
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated:  12/31/1969
Clinical Research of Homestead
2314
mi
from 91732
Homestead, FL
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated: 12/31/1969
Clinical Research of Homestead
2314
mi
from 91732
Homestead, FL
Click here to add this to my saved trials
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
A Phase 2, Randomized, Open-Label Study of Infliximab and Lower Exposure Corticosteroids vs Methylprednisolone and Higher Exposure Oral Corticosteroids for the Management of Immune-Related Severe or Persistent Diarrhea in Patients Treated With Yervoy (Ipilimumab) and/or Opdivo (Nivolumab)
Status: Enrolling
Updated:  12/31/1969
Local Institution
653
mi
from 91732
Albuquerque, NM
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
A Phase 2, Randomized, Open-Label Study of Infliximab and Lower Exposure Corticosteroids vs Methylprednisolone and Higher Exposure Oral Corticosteroids for the Management of Immune-Related Severe or Persistent Diarrhea in Patients Treated With Yervoy (Ipilimumab) and/or Opdivo (Nivolumab)
Status: Enrolling
Updated: 12/31/1969
Local Institution
653
mi
from 91732
Albuquerque, NM
Click here to add this to my saved trials
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
A Phase 2, Randomized, Open-Label Study of Infliximab and Lower Exposure Corticosteroids vs Methylprednisolone and Higher Exposure Oral Corticosteroids for the Management of Immune-Related Severe or Persistent Diarrhea in Patients Treated With Yervoy (Ipilimumab) and/or Opdivo (Nivolumab)
Status: Enrolling
Updated:  12/31/1969
University of Colorado Cancer Center
825
mi
from 91732
Aurora, CO
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
A Phase 2, Randomized, Open-Label Study of Infliximab and Lower Exposure Corticosteroids vs Methylprednisolone and Higher Exposure Oral Corticosteroids for the Management of Immune-Related Severe or Persistent Diarrhea in Patients Treated With Yervoy (Ipilimumab) and/or Opdivo (Nivolumab)
Status: Enrolling
Updated: 12/31/1969
University of Colorado Cancer Center
825
mi
from 91732
Aurora, CO
Click here to add this to my saved trials
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
A Phase 2, Randomized, Open-Label Study of Infliximab and Lower Exposure Corticosteroids vs Methylprednisolone and Higher Exposure Oral Corticosteroids for the Management of Immune-Related Severe or Persistent Diarrhea in Patients Treated With Yervoy (Ipilimumab) and/or Opdivo (Nivolumab)
Status: Enrolling
Updated:  12/31/1969
Atlantic Health System
2407
mi
from 91732
Morristown, NJ
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
A Phase 2, Randomized, Open-Label Study of Infliximab and Lower Exposure Corticosteroids vs Methylprednisolone and Higher Exposure Oral Corticosteroids for the Management of Immune-Related Severe or Persistent Diarrhea in Patients Treated With Yervoy (Ipilimumab) and/or Opdivo (Nivolumab)
Status: Enrolling
Updated: 12/31/1969
Atlantic Health System
2407
mi
from 91732
Morristown, NJ
Click here to add this to my saved trials
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
A Phase 2, Randomized, Open-Label Study of Infliximab and Lower Exposure Corticosteroids vs Methylprednisolone and Higher Exposure Oral Corticosteroids for the Management of Immune-Related Severe or Persistent Diarrhea in Patients Treated With Yervoy (Ipilimumab) and/or Opdivo (Nivolumab)
Status: Enrolling
Updated:  12/31/1969
University of California at Los Angeles
25
mi
from 91732
Los Angeles, CA
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
A Phase 2, Randomized, Open-Label Study of Infliximab and Lower Exposure Corticosteroids vs Methylprednisolone and Higher Exposure Oral Corticosteroids for the Management of Immune-Related Severe or Persistent Diarrhea in Patients Treated With Yervoy (Ipilimumab) and/or Opdivo (Nivolumab)
Status: Enrolling
Updated: 12/31/1969
University of California at Los Angeles
25
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
A Phase 2, Randomized, Open-Label Study of Infliximab and Lower Exposure Corticosteroids vs Methylprednisolone and Higher Exposure Oral Corticosteroids for the Management of Immune-Related Severe or Persistent Diarrhea in Patients Treated With Yervoy (Ipilimumab) and/or Opdivo (Nivolumab)
Status: Enrolling
Updated:  12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
2134
mi
from 91732
Tampa, FL
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
A Phase 2, Randomized, Open-Label Study of Infliximab and Lower Exposure Corticosteroids vs Methylprednisolone and Higher Exposure Oral Corticosteroids for the Management of Immune-Related Severe or Persistent Diarrhea in Patients Treated With Yervoy (Ipilimumab) and/or Opdivo (Nivolumab)
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
2134
mi
from 91732
Tampa, FL
Click here to add this to my saved trials
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
A Phase 2, Randomized, Open-Label Study of Infliximab and Lower Exposure Corticosteroids vs Methylprednisolone and Higher Exposure Oral Corticosteroids for the Management of Immune-Related Severe or Persistent Diarrhea in Patients Treated With Yervoy (Ipilimumab) and/or Opdivo (Nivolumab)
Status: Enrolling
Updated:  12/31/1969
Huntsman Cancer Institute at University of Utah
573
mi
from 91732
Salt Lake City, UT
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
A Phase 2, Randomized, Open-Label Study of Infliximab and Lower Exposure Corticosteroids vs Methylprednisolone and Higher Exposure Oral Corticosteroids for the Management of Immune-Related Severe or Persistent Diarrhea in Patients Treated With Yervoy (Ipilimumab) and/or Opdivo (Nivolumab)
Status: Enrolling
Updated: 12/31/1969
Huntsman Cancer Institute at University of Utah
573
mi
from 91732
Salt Lake City, UT
Click here to add this to my saved trials
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
A Phase 2, Randomized, Open-Label Study of Infliximab and Lower Exposure Corticosteroids vs Methylprednisolone and Higher Exposure Oral Corticosteroids for the Management of Immune-Related Severe or Persistent Diarrhea in Patients Treated With Yervoy (Ipilimumab) and/or Opdivo (Nivolumab)
Status: Enrolling
Updated:  12/31/1969
Winship Cancer Institute at Emory University
1922
mi
from 91732
Atlanta, GA
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
A Phase 2, Randomized, Open-Label Study of Infliximab and Lower Exposure Corticosteroids vs Methylprednisolone and Higher Exposure Oral Corticosteroids for the Management of Immune-Related Severe or Persistent Diarrhea in Patients Treated With Yervoy (Ipilimumab) and/or Opdivo (Nivolumab)
Status: Enrolling
Updated: 12/31/1969
Winship Cancer Institute at Emory University
1922
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
A Phase 2, Randomized, Open-Label Study of Infliximab and Lower Exposure Corticosteroids vs Methylprednisolone and Higher Exposure Oral Corticosteroids for the Management of Immune-Related Severe or Persistent Diarrhea in Patients Treated With Yervoy (Ipilimumab) and/or Opdivo (Nivolumab)
Status: Enrolling
Updated:  12/31/1969
University of Louisville
1812
mi
from 91732
Louisville, KY
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
A Phase 2, Randomized, Open-Label Study of Infliximab and Lower Exposure Corticosteroids vs Methylprednisolone and Higher Exposure Oral Corticosteroids for the Management of Immune-Related Severe or Persistent Diarrhea in Patients Treated With Yervoy (Ipilimumab) and/or Opdivo (Nivolumab)
Status: Enrolling
Updated: 12/31/1969
University of Louisville
1812
mi
from 91732
Louisville, KY
Click here to add this to my saved trials
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
A Phase 2, Randomized, Open-Label Study of Infliximab and Lower Exposure Corticosteroids vs Methylprednisolone and Higher Exposure Oral Corticosteroids for the Management of Immune-Related Severe or Persistent Diarrhea in Patients Treated With Yervoy (Ipilimumab) and/or Opdivo (Nivolumab)
Status: Enrolling
Updated:  12/31/1969
University of Michigan
1932
mi
from 91732
Ann Arbor, MI
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
A Phase 2, Randomized, Open-Label Study of Infliximab and Lower Exposure Corticosteroids vs Methylprednisolone and Higher Exposure Oral Corticosteroids for the Management of Immune-Related Severe or Persistent Diarrhea in Patients Treated With Yervoy (Ipilimumab) and/or Opdivo (Nivolumab)
Status: Enrolling
Updated: 12/31/1969
University of Michigan
1932
mi
from 91732
Ann Arbor, MI
Click here to add this to my saved trials
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
A Phase 2, Randomized, Open-Label Study of Infliximab and Lower Exposure Corticosteroids vs Methylprednisolone and Higher Exposure Oral Corticosteroids for the Management of Immune-Related Severe or Persistent Diarrhea in Patients Treated With Yervoy (Ipilimumab) and/or Opdivo (Nivolumab)
Status: Enrolling
Updated:  12/31/1969
NYU Langone Medical Center
2434
mi
from 91732
New York, NY
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
A Phase 2, Randomized, Open-Label Study of Infliximab and Lower Exposure Corticosteroids vs Methylprednisolone and Higher Exposure Oral Corticosteroids for the Management of Immune-Related Severe or Persistent Diarrhea in Patients Treated With Yervoy (Ipilimumab) and/or Opdivo (Nivolumab)
Status: Enrolling
Updated: 12/31/1969
NYU Langone Medical Center
2434
mi
from 91732
New York, NY
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
356
mi
from 91732
Chandler, AZ
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
356
mi
from 91732
Chandler, AZ
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
427
mi
from 91732
Tucson, AZ
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
427
mi
from 91732
Tucson, AZ
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
113
mi
from 91732
Chula Vista, CA
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
113
mi
from 91732
Chula Vista, CA
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
207
mi
from 91732
Fresno, CA
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
207
mi
from 91732
Fresno, CA
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
21
mi
from 91732
Garden Grove, CA
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
21
mi
from 91732
Garden Grove, CA
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
13
mi
from 91732
Huntington Park, CA
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
13
mi
from 91732
Huntington Park, CA
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
105
mi
from 91732
La Mesa, CA
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
105
mi
from 91732
La Mesa, CA
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
13
mi
from 91732
Los Angeles, CA
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
13
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
95
mi
from 91732
Poway, CA
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
95
mi
from 91732
Poway, CA
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
36
mi
from 91732
Rialto, CA
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
36
mi
from 91732
Rialto, CA
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
105
mi
from 91732
San Diego, CA
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
105
mi
from 91732
San Diego, CA
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
815
mi
from 91732
Englewood, CO
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
815
mi
from 91732
Englewood, CO
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2103
mi
from 91732
Gainesville, FL
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2103
mi
from 91732
Gainesville, FL
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2315
mi
from 91732
Hialeah, FL
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2315
mi
from 91732
Hialeah, FL
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2122
mi
from 91732
Inverness, FL
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2122
mi
from 91732
Inverness, FL
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2151
mi
from 91732
Lakewood Ranch, FL
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2151
mi
from 91732
Lakewood Ranch, FL
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from 91732
Miami Lakes, FL
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from 91732
Miami Lakes, FL
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2294
mi
from 91732
Wellington, FL
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2294
mi
from 91732
Wellington, FL
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1908
mi
from 91732
Marietta, GA
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1908
mi
from 91732
Marietta, GA
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1793
mi
from 91732
Indianapolis, IN
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1793
mi
from 91732
Indianapolis, IN
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1506
mi
from 91732
Bastrop, LA
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1506
mi
from 91732
Bastrop, LA
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1655
mi
from 91732
New Orleans, LA
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1655
mi
from 91732
New Orleans, LA
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1493
mi
from 91732
West Monroe, LA
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1493
mi
from 91732
West Monroe, LA
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1611
mi
from 91732
Flowood, MS
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1611
mi
from 91732
Flowood, MS
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
208
mi
from 91732
Las Vegas, NV
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
208
mi
from 91732
Las Vegas, NV
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2434
mi
from 91732
Brooklyn, NY
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2434
mi
from 91732
Brooklyn, NY
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2435
mi
from 91732
New York, NY
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2213
mi
from 91732
Fayetteville, NC
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2213
mi
from 91732
Fayetteville, NC
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2290
mi
from 91732
Greenville, NC
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2290
mi
from 91732
Greenville, NC
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2093
mi
from 91732
Statesville, NC
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2093
mi
from 91732
Statesville, NC
Click here to add this to my saved trials